Buchumschlag

Editorial: Prevention of Upper GI Bleeding in Users of Anti‐Thrombotic Drugs—P‐ CABs Versus PPIs . Authors' Reply

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Min Joo Yoon, Soyoung Lee, Hye‐Kyung Jung, Min‐ho Kim, Suna Yu, Eui Sun Jeong, Chung Hyun Tae
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2026
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: Prevention of Upper GI Bleeding in Users of Anti‐Thrombotic Drugs—P‐ CABs Versus PPIs
von: Ali S. Taha
Veröffentlicht: (2026)

P‐ CAB vs. PPI for Upper Gastrointestinal Bleeding Prevention in Patients With Atherothrombotic Disease on Antithrombotic Therapy: A CDM Cohort Study
von: Min Joo Yoon, et al.
Veröffentlicht: (2026)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
von: Fai Fai Ho, et al.
Veröffentlicht: (2025)

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
von: Jonggi Choi
Veröffentlicht: (2025)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
von: Pinelopi Arvaniti, et al.
Veröffentlicht: (2025)

Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial. Authors' Reply
von: Nauzer Forbes, et al.
Veröffentlicht: (2024)

Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows? Authors' Reply
von: Ryan M. Mathias, et al.
Veröffentlicht: (2025)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
von: Ramin Ebrahimi, et al.
Veröffentlicht: (2025)

Letter: Interpreting Apparent P‐ CAB Superiority for Antithrombotic‐Associated Upper Gastrointestinal Bleeding
von: Xiaoqing Yang, et al.
Veröffentlicht: (2026)

Editorial: Beyond Clinical Trials—Real‐World Data Suggest Usefulness of GLP‐1 RAs in MASLD Treatment. Authors' Reply
von: Chia‐Chih Kuo, et al.
Veröffentlicht: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
von: Jianhui Zhao, et al.
Veröffentlicht: (2024)

Editorial: To Stop or Not to Stop, Is It Still a Question? Authors' Reply
von: Jeongkuk Seo, et al.
Veröffentlicht: (2024)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
von: Máté Szilcz, et al.
Veröffentlicht: (2025)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
von: Shuaibing Ying, et al.
Veröffentlicht: (2026)

Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma
von: Kanghee Park, et al.
Veröffentlicht: (2025)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky. Authors' Reply
von: Raj Vuppalanchi, et al.
Veröffentlicht: (2025)

Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply
von: Shintaro Akiyama, et al.
Veröffentlicht: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
von: J. M. Schattenberg, et al.
Veröffentlicht: (2026)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
von: Suprabhat Giri, et al.
Veröffentlicht: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
von: Federica Tavaglione, et al.
Veröffentlicht: (2025)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
von: Parul Tandon, et al.
Veröffentlicht: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
von: Bharati Kochar, et al.
Veröffentlicht: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
von: Virginia Solitano, et al.
Veröffentlicht: (2024)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects. Authors' Reply
von: David Mehdi Asgher Niazi, et al.
Veröffentlicht: (2026)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition? Authors' Reply
von: Irene Spinelli, et al.
Veröffentlicht: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2025)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
von: Jeffrey D McCurdy, et al.
Veröffentlicht: (2025)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
von: Daniel Q. Huang, et al.
Veröffentlicht: (2026)

Editorial: The Devil Is in the Detail—Interpreting the Findings of Network Meta‐Analyses. Authors' Reply
von: Mohammad Shehab, et al.
Veröffentlicht: (2025)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
von: Nina Dominik, et al.
Veröffentlicht: (2024)

Editorial: Resecting Assumptions—Do Proctocolectomy Guidelines Hold Up? Author's Reply
von: Erik Lundqvist, et al.
Veröffentlicht: (2025)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
von: Mohamed El‐Kassas, et al.
Veröffentlicht: (2025)

Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply
von: Lucie Simonis, et al.
Veröffentlicht: (2025)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
von: Mary Yue Wang, et al.
Veröffentlicht: (2026)

Editorial: Assessing the Prognosis of Patients With HBV and ACLF—Comorbidities Matter. Authors' Reply
von: Jiong Yu, et al.
Veröffentlicht: (2024)

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply
von: Isabella Lurje, et al.
Veröffentlicht: (2025)

Editorial: TIPS in the Era of Aging and Metabolic Comorbidity—Rethinking Risks and Rewards. Authors Reply
von: Michelle Spaan, et al.
Veröffentlicht: (2026)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy—Authors' Reply
von: Tanat Saeoui, et al.
Veröffentlicht: (2025)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity? Authors' Reply
von: Eric Lawitz, et al.
Veröffentlicht: (2025)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply
von: Hong‐Li Liu, et al.
Veröffentlicht: (2026)